Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pulmonx's Business Segments
Pulmonx's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 23
Regions Reported
3
Pulmonx does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- EMEA34%
- Asia Pacific3.2%
- Other International Geographical Areas0.6%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| EMEA | $ 8 | 34% |
| Asia Pacific | $ 1 | 3.2% |
| Other International Geographical Areas | $ 0 | 0.6% |
Description of Pulmonx
Pulmonx Corporation is a globally recognized medical device company that specializes in the development and commercialization of minimally invasive solutions for patients suffering from chronic obstructive pulmonary disease (COPD) and other lung diseases. The company is dedicated to improving the lives of patients by providing innovative and effective treatment options that are less invasive than traditional surgical procedures.
Pulmonx was founded in 1998 by Rodney Perkins and Rodney Brenneman, two pioneers in the field of interventional pulmonology. The company's headquarters are located in Redwood City, California, and it has additional offices and research facilities across Europe, Asia, and Australia.
The core technology developed by Pulmonx is called Zephyr Endobronchial Valve (EBV) System. This system consists of small, one-way valves that are inserted into the lungs through a minimally invasive bronchoscopic procedure. The valves are designed to redirect airflow to healthier lung regions, which helps to reduce hyperinflation and improve lung function in patients with severe emphysema.
The Zephyr EBV System has been extensively researched and clinically tested in various studies worldwide. It has received regulatory approvals in many countries, including the United States, Europe, China, and Japan. The system has been proven to provide significant benefits to patients, such as improved lung function, exercise tolerance, and quality of life.
Pulmonx also offers a comprehensive suite of products and services to support the successful implementation of its treatments. This includes medical training and education for healthcare professionals, patient selection tools, and ongoing patient monitoring solutions. The company has a dedicated team of experts who work closely with physicians, hospitals, and healthcare systems to ensure optimal patient outcomes.
In addition to its focus on COPD treatment, Pulmonx is actively involved in research and development efforts to explore new applications of its technology. The company is studying the use of the Zephyr EBV System in other lung diseases, such as bronchiectasis and chronic bronchitis. These efforts highlight Pulmonx's commitment to advancing the field of interventional pulmonology and providing innovative solutions for patients with respiratory diseases.
Pulmonx has received numerous awards and recognition for its contributions to the medical field. The company's groundbreaking technology and commitment to patient care have earned it a strong reputation among healthcare professionals and patients alike. With a dedicated and passionate team, Pulmonx continues to push the boundaries of medical innovation and improve the lives of individuals suffering from lung diseases worldwide.
Pulmonx was founded in 1998 by Rodney Perkins and Rodney Brenneman, two pioneers in the field of interventional pulmonology. The company's headquarters are located in Redwood City, California, and it has additional offices and research facilities across Europe, Asia, and Australia.
The core technology developed by Pulmonx is called Zephyr Endobronchial Valve (EBV) System. This system consists of small, one-way valves that are inserted into the lungs through a minimally invasive bronchoscopic procedure. The valves are designed to redirect airflow to healthier lung regions, which helps to reduce hyperinflation and improve lung function in patients with severe emphysema.
The Zephyr EBV System has been extensively researched and clinically tested in various studies worldwide. It has received regulatory approvals in many countries, including the United States, Europe, China, and Japan. The system has been proven to provide significant benefits to patients, such as improved lung function, exercise tolerance, and quality of life.
Pulmonx also offers a comprehensive suite of products and services to support the successful implementation of its treatments. This includes medical training and education for healthcare professionals, patient selection tools, and ongoing patient monitoring solutions. The company has a dedicated team of experts who work closely with physicians, hospitals, and healthcare systems to ensure optimal patient outcomes.
In addition to its focus on COPD treatment, Pulmonx is actively involved in research and development efforts to explore new applications of its technology. The company is studying the use of the Zephyr EBV System in other lung diseases, such as bronchiectasis and chronic bronchitis. These efforts highlight Pulmonx's commitment to advancing the field of interventional pulmonology and providing innovative solutions for patients with respiratory diseases.
Pulmonx has received numerous awards and recognition for its contributions to the medical field. The company's groundbreaking technology and commitment to patient care have earned it a strong reputation among healthcare professionals and patients alike. With a dedicated and passionate team, Pulmonx continues to push the boundaries of medical innovation and improve the lives of individuals suffering from lung diseases worldwide.
Pulmonx Corporation is a medical device company focusing primarily on innovative therapies for patients with lung diseases, particularly those suffering from chronic obstructive pulmonary disease (COPD) and other conditions affecting lung function. Their main offerings revolve around the use of endobronchial technologies aimed at improving lung function and enhancing the quality of life for patients with compromised lung capacity. Below is an extensive description of the segments, products, and services that Pulmonx Corporation provides:
Segments
1. Medical Devices Sector:
- This sector encompasses the development and distribution of specialized devices designed for minimally invasive procedures aimed at treating lung diseases.
2. Therapeutic Solutions:
- Pulmonx focuses on providing therapeutic interventions that can restore lung function through reduction in hyperinflation, thereby improving patients’ breathing and overall pulmonary health.
3. Clinical Services:
- Pulmonx offers clinical support through various programs designed to educate healthcare providers about the proper use of their devices and how they can benefit patients.
Products
1. Zephyr Valve:
- The Zephyr Endobronchial Valve is one of Pulmonxs flagship products. It is a minimally invasive, outpatient procedure designed to treat emphysema, a severe form of COPD.
- Functionality: The valve helps to reduce air trapping in the lungs, allowing the affected lobes to deflate and enabling the healthier portions of the lungs to function more effectively.
- Deployment: The Zephyr Valve is non-surgically placed using a bronchoscope and does not require incisions, which minimizes recovery time and hospital stay for patients.
2. Pulmonx Assessment Tools:
- Pulmonx also provides a range of proprietary diagnostic tools to assess the suitability of patients for the Zephyr Valve.
- Lung Volume Reduction: These assessments help determine the effectiveness of lung volume reduction therapies and are critical in ensuring patients receive personalized treatment options.
3. Training and Education Programs:
- Pulmonx offers extensive training for healthcare professionals on the usage of their products and the underlying principles of endobronchial therapy.
- These programs also involve workshops and simulation systems to enhance procedural skills and patient management.
4. Patient Support Programs:
- Developed to assist patients throughout their treatment journey, ensuring they are informed about the procedure, post-operative care, and what to expect during their recovery.
- These programs often include access to resources like counseling and patient education materials aimed at understanding COPD and its management.
Services
1. Clinical Trials and Research:
- Pulmonx is heavily invested in clinical research to validate the efficacy of their devices. They often collaborate with research institutions and hospitals to support clinical studies aimed at improving their offerings and patient outcomes.
2. Consultative Services:
- The corporation offers consultative services for healthcare providers focusing on how best to integrate Pulmonx technologies into their clinical practice. This service helps in optimizing treatment pathways for patients with emphysema and respiratory issues.
3. Data Analytics:
- To enhance the patient care experience, Pulmonx employs data analytics to monitor treatment outcomes. This data can help healthcare providers track the effectiveness of therapies over time, leading to improved patient management strategies.
4. Patient Registry:
- Pulmonx may participate in or facilitate patient registry initiatives aimed at collecting data on patient experiences and outcomes following the use of their products. This information is valuable for ongoing research and product development.
5. Partnerships with Healthcare Systems:
- The company collaborates with various healthcare systems to implement protocols that incorporate their devices into standard practice for treating COPD.
Conclusion
Pulmonx Corporation represents a critical player in the field of pulmonary care through its innovative devices and comprehensive support services that enhance the quality of care provided to patients suffering from life-altering lung conditions. Their commitment to research, training, and patient education positions them as a leader in this niche market, aimed at transforming the treatment landscape for patients with compromised lung health.
Segments
1. Medical Devices Sector:
- This sector encompasses the development and distribution of specialized devices designed for minimally invasive procedures aimed at treating lung diseases.
2. Therapeutic Solutions:
- Pulmonx focuses on providing therapeutic interventions that can restore lung function through reduction in hyperinflation, thereby improving patients’ breathing and overall pulmonary health.
3. Clinical Services:
- Pulmonx offers clinical support through various programs designed to educate healthcare providers about the proper use of their devices and how they can benefit patients.
Products
1. Zephyr Valve:
- The Zephyr Endobronchial Valve is one of Pulmonxs flagship products. It is a minimally invasive, outpatient procedure designed to treat emphysema, a severe form of COPD.
- Functionality: The valve helps to reduce air trapping in the lungs, allowing the affected lobes to deflate and enabling the healthier portions of the lungs to function more effectively.
- Deployment: The Zephyr Valve is non-surgically placed using a bronchoscope and does not require incisions, which minimizes recovery time and hospital stay for patients.
2. Pulmonx Assessment Tools:
- Pulmonx also provides a range of proprietary diagnostic tools to assess the suitability of patients for the Zephyr Valve.
- Lung Volume Reduction: These assessments help determine the effectiveness of lung volume reduction therapies and are critical in ensuring patients receive personalized treatment options.
3. Training and Education Programs:
- Pulmonx offers extensive training for healthcare professionals on the usage of their products and the underlying principles of endobronchial therapy.
- These programs also involve workshops and simulation systems to enhance procedural skills and patient management.
4. Patient Support Programs:
- Developed to assist patients throughout their treatment journey, ensuring they are informed about the procedure, post-operative care, and what to expect during their recovery.
- These programs often include access to resources like counseling and patient education materials aimed at understanding COPD and its management.
Services
1. Clinical Trials and Research:
- Pulmonx is heavily invested in clinical research to validate the efficacy of their devices. They often collaborate with research institutions and hospitals to support clinical studies aimed at improving their offerings and patient outcomes.
2. Consultative Services:
- The corporation offers consultative services for healthcare providers focusing on how best to integrate Pulmonx technologies into their clinical practice. This service helps in optimizing treatment pathways for patients with emphysema and respiratory issues.
3. Data Analytics:
- To enhance the patient care experience, Pulmonx employs data analytics to monitor treatment outcomes. This data can help healthcare providers track the effectiveness of therapies over time, leading to improved patient management strategies.
4. Patient Registry:
- Pulmonx may participate in or facilitate patient registry initiatives aimed at collecting data on patient experiences and outcomes following the use of their products. This information is valuable for ongoing research and product development.
5. Partnerships with Healthcare Systems:
- The company collaborates with various healthcare systems to implement protocols that incorporate their devices into standard practice for treating COPD.
Conclusion
Pulmonx Corporation represents a critical player in the field of pulmonary care through its innovative devices and comprehensive support services that enhance the quality of care provided to patients suffering from life-altering lung conditions. Their commitment to research, training, and patient education positions them as a leader in this niche market, aimed at transforming the treatment landscape for patients with compromised lung health.